Paid Clinical Trials Yuma

Discover 25 paid clinical trials in Yuma, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 25

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineA 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Imperial CA, San Diego CA, Phoenix AZ, Scottsdale AZshow 73 more

Code:

NCT04396574

Conditions

Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Lasmiditan

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Yuma AZ, Orange CA, Los Angeles CA, Colorado Springs COshow 37 more

Code:

NCT06077760

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

V940

Pembrolizumab

Placebo

ALTO-100 in Bipolar Disorder with Depression (BD-D)ALTO-100 in Bipolar Disorder with Depression (BD-D)

Recruiting

PHASE2

Sponsor:

Alto Neuroscience

Location:

Yuma AZ, Imperial CA, Phoenix AZ, Oceanside CAshow 11 more

Code:

NCT06656416

Conditions

Bipolar Disorder I or II with a Major Depressive Episode

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

ALTO-100

Placebo

Study to Assess the Safety and Effectiveness of NMRA-335140-501Study to Assess the Safety and Effectiveness of NMRA-335140-501

Recruiting

PHASE3

Sponsor:

Neumora Therapeutics, Inc.

Location:

Imperial CA, Temecula CA, Phoenix AZ, Oceanside CAshow 83 more

Code:

NCT06029439

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

NMRA-335140

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityA Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting

PHASE3

Sponsor:

Amgen

Location:

Glendale AZ, La Jolla CA, Phoenix AZ, Chandler AZshow 38 more

Code:

NCT06104124

Conditions

Sjogren's Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dazodalibep

Placebo

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsA Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Yuma AZ, Fountain Valley CA, Clovis CA, Ogden UTshow 19 more

Code:

NCT05653219

Conditions

Primary Immune Thrombocytopenia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ianalumab

Eltrombopag

Placebo

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Yuma AZ, Rancho Mirage CA, Phoenix AZ, Chandler AZshow 47 more

Code:

NCT04928846

Conditions

Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Telisotuzumab Vedotin

Docetaxel

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting

PHASE2

PHASE3

Sponsor:

Regeneron Pharmaceuticals

Location:

Yuma AZ, Rancho Mirage CA, Redlands CA, Tucson AZshow 18 more

Code:

NCT05785767

Conditions

Advanced Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

fianlimab

cemiplimab

Placebo

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderA Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Recruiting

PHASE2

Sponsor:

Sirtsei Pharmaceuticals, Inc.

Location:

Imperial CA, Lemon Grove CA, Phoenix AZ, Oceanside CAshow 38 more

Code:

NCT06254612

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

SP-624

Placebo

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Recruiting

PHASE3

Sponsor:

ArriVent BioPharma, Inc.

Location:

Yuma AZ, San Diego CA, Orange CA, Fullerton CAshow 65 more

Code:

NCT05607550

Conditions

Metastatic Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

EGFR Exon 20 Mutations

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

furmonertinib 240 mg oral, daily

furmonertinib 160 mg oral, daily

platinum-based chemotherapy